Some studies have indicated that cancer cells carrying BRCA1/2 mutations are 1000 times more sensitive to PARP inhibitors than cancer cells carrying wild-type BRCA. However, BRCA1 or BRCA2 mutations account for only a small percentage of all breast cancers and ovarian cancers. Here, PARP1 is linked to breast carcinoma.